PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors

Cancer Research

Volumn 72, Issue 13, 2012, Pages 3405-3413

  Keng, Vincent W ^a,b,c   Rahrmann, Eric P ^a,b,c   Watson, Adrienne L ^a,b,c   Tschida, Barbara R ^a,b,c   Moertel, Christopher L ^b,c   Jessen, Walter J ^d,e   Rizvi, Tilat A ^d   Collins, Margaret H ^d   Ratner, Nancy ^d   Largaespada, David A ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^e Biomarker Center of Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOSS; GENETIC SCREENING; GROWTH RATE; HAPLOINSUFFICIENCY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NEURAL STEM CELL; NEUROFIBROMA; NEUROFIBROMATOSIS 1 GENE; NONHUMAN; PHENOTYPE; PHOSPHATASE AND TENSIN GENE; PRIORITY JOURNAL; SCHWANN CELL; VALIDATION STUDY;

ANIMALS; DISEASE PROGRESSION; HUMANS; MICE; MICE, TRANSGENIC; NERVE SHEATH NEOPLASMS; NEUROFIBROMIN 1; OLIGOPEPTIDES; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; PTEN PHOSPHOHYDROLASE; SCHWANN CELLS;

EID: 84863593847     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-4092     Document Type: Article

References (23)

1. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61:1-14; quiz 5-6.
2. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6. (Pubitemid 30033170)
3. Rosenfeld A, Listernick R, Charrow J, Goldman S. Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst 2010;26:663-7.
4. Maertens O, Brems H, Vandesompele J, De Raedt T, Heyns I, Rosenbaum T, et al. Comprehensive NF1 screening on cultured Schwann cells from neurofibromas. Hum Mutat 2006;27:1030-40. (Pubitemid 44454056)
5. Serra E, Ars E, Ravella A, Sanchez A, Puig S, Rosenbaum T, et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 2001;108:416-29. (Pubitemid 32492448)
6. Serra E, Puig S, Otero D, Gaona A, Kruyer H, Ars E, et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am J Hum Genet 1997;61:512-9. (Pubitemid 27418392)
7. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? Glia 2008;56:1590-605.
8. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009;27:264-74.
9. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009;69:8150-6.
10. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009;323:1747-50.
11. WuJ, WilliamsJP,Rizvi TA,Kordich JJ, WitteD, MeijerD, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008;13:105-16.
12. Hollander MC, BlumenthalGM,Dennis PA.PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011;11:289-301.
13. Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, et al. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A 2009;106:19479-84.
14. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-2. (Pubitemid 34464899)
15. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 2005;65:5172-80. (Pubitemid 40827326)
16. Jaegle M, Ghazvini M, Mandemakers W, Piirsoo M, Driegen S, Levavasseur F, et al. The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev 2003;17:1380-91. (Pubitemid 36666007)
17. Viskochil DH. It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. J Clin Invest 2003;112:1791-3. (Pubitemid 38063701)
18. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004;64:3718-24. (Pubitemid 38657953)
19. Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002;21:7453-63. (Pubitemid 35305572)
20. Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, et al. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res 2010;16:5048-57.
21. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, et al. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-91.
22. Rodriguez EF, Scheithauer BW, Giannini C, Rynearson A, Cen L, Hoesley B, et al. PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. Acta Neuropathol 2011;121:407-20.
23. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65:2755-60. (Pubitemid 40490077)